PRN: Elsevier's Journal of Diabetes and its Complications Announces New Editorial Team and Expansion

PRN: Elsevier's Journal of Diabetes and its Complications Announces New Editorial Team and Expansion.

Persone Andrew Miller Elsevier, Steven Kahn, Stefano Del Prato, Vivian A. Fonseca, April
Luoghi Italia, Pisa, Inghilterra, Oxford, Louisiana, Amsterdam, Seattle, New Orleans, Wé
Organizzazioni Company Codes, Elsevier's, Science and Medicine at the American Diabetes Association, NYSE, London Stock Exchange
Argomenti internet, sport, storia, impresa

02/apr/2012 13:30:48 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Elsevier's Journal of Diabetes and its Complications Announces New Editorial Team and Expansion


OXFORD, England, April 2, 2012 /PRNewswire/ --

Global diabetes epidemic increases demand for high-quality research publications

Elsevier's Journal of Diabetes and its Complications is pleased to announce the appointment of a high-profile senior editorial team who will oversee a significant increase in the number of quality papers published in 2012. The increasing prevalence and impact of diabetes worldwide means that means that the journal has to grow in quality and size to meet the demands of clinicians at the forefront of the epidemic.

The new Editor-in-Chief is Vivian A. Fonseca, MD, FRCP, Professor of Medicine, Tullis-Tulane Alumni Chair in Diabetes, and Chief of the Section of Endocrinology at Tulane University Medical Center in New Orleans, Louisiana. Professor Fonseca is also President for Science and Medicine at the American Diabetes Association.

On his new appointment, Professor Fonseca commented, "We are facing a major international public health crisis with the increase in diabetes. Dissemination of high-quality research will help stem this epidemic. I am delighted to have the opportunity to play a significant role in this aspect as journal editor. Our aim is to publish high-quality articles covering all aspects of diabetes, with an emphasis on translating research into clinical practice."

Drs. Stefano Del Prato (Pisa, Italy) and Steven Kahn (Seattle, USA) have joined the journal as Associate Editors. Drs. Del Prato and Kahn are internationally recognized figures in the diabetes community with research interests spanning basic science through to clinical.

Andrew Miller, Executive Publisher of Journal of Diabetes and its Complications, stated, "Elsevier is delighted to appoint a senior editorial team of such experience and caliber. Diabetes is a huge and growing challenge and the journal is expanding to address the needs of researchers and clinicians worldwide."

About the Journal of Diabetes and its Complications

The primary aim of Journal of Diabetes and Its Complications is to provide usable information for practitioners caring for patients with diabetes who are at risk of developing further complications. The journal also acts as a forum for the dissemination of experimental work that may inform current thinking in the field of diabetes research.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and heal! th care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Andrew Miller

blog comments powered by Disqus è un servizio offerto da Factotum Srl